Global Monoclonal Antibodies Market is Projected to Reach USD 520 Billion by 2030

Global Monoclonal Antibodies Market is Projected to Reach USD 520 Billion by 2030

by

The Global Monoclonal Antibodies Market was valued at USD 254.38 Billion in 2023 and is projected to reach USD 534.9 Billion by 2030, expanding at a CAGR of 11.2% during 2024–2030.

REQUESTSAMPLE:https://virtuemarketresearch.com/report/monoclonal-antibodies-market/request-sample

Industry Overview

Monoclonal antibody (mAb) therapy is a form of immunotherapy that uses laboratory-produced antibodies designed to bind specifically to targeted antigens. These antibodies are identical clones derived from a single parent immune cell and exhibit high specificity (monovalent affinity) toward particular proteins or cells.

Monoclonal antibodies are widely applied in:

  • Oncology

  • Autoimmune disorders

  • Infectious diseases

  • Cardiovascular diseases

  • Neurological disorders

  • Molecular biology and biochemical research

Therapeutic mAbs function by:

  • Blocking abnormal cell growth

  • Preventing metastasis

  • Modulating immune response

  • Delivering targeted drug therapies

The industry includes:

  • Anti-cancer monoclonal antibodies

  • Immunological monoclonal antibodies

  • Neuropharmacological monoclonal antibodies

  • Anti-infective monoclonal antibodies

  • Veterinary monoclonal antibodies

Market Growth Drivers

1. Strong R&D and Product Innovation

A major growth catalyst is continuous research and development aimed at producing highly targeted therapies for complex diseases.

For example, in June 2021, the European Commission approved a combination therapy of OPDIVO and Yervoy developed by Bristol Myers Squibb for malignant pleural mesothelioma, expanding the product’s therapeutic footprint.

Key factors supporting growth:

  • Increasing government funding

  • Expedited regulatory pathways

  • Expanding drug pipelines

  • Advanced genetic engineering platforms

  • Adoption of next-generation sequencing (NGS)

2. Expanding Oncology Applications

The oncology segment represents the largest indication category due to rising global cancer incidence.

Monoclonal antibodies are used in treating:

  • Non-small cell lung cancer

  • Breast cancer

  • Colorectal cancer

  • Ovarian cancer

  • Melanoma

  • Gastric cancer

  • Hodgkin’s lymphoma

Compared to traditional chemotherapy, mAbs offer:

  • Higher target specificity

  • Reduced systemic toxicity

  • Fewer side effects

The growing availability of cost-effective biosimilar monoclonal antibodies further enhances accessibility and market expansion.

3. Growing Demand for Biosimilars

Biosimilar monoclonal antibodies aim to:

  • Reduce treatment costs

  • Improve patient access

  • Address healthcare budget pressures

Governments and healthcare providers increasingly support biosimilars to control escalating biologics expenditure.

Market Restraints

1. Strict Regulatory Framework

Approval of monoclonal antibody therapies involves:

  • Extensive clinical trials

  • Strict safety and efficacy requirements

  • Lengthy regulatory review timelines

Many candidates fail to meet regulatory benchmarks, delaying commercialization and increasing development costs.

2. High Manufacturing Costs

Therapeutic mAbs are among the most expensive drugs globally due to:

  • Large-scale mammalian cell culture production

  • GMP-compliant purification processes

  • Complex biologics manufacturing

Emerging alternatives such as plant-based production systems are being explored to reduce costs.

Market Segmentation Analysis

By Source

  • Murine

  • Chimeric

  • Humanized

  • Human

Human mAbs – Largest Segment

The Human monoclonal antibodies segment holds the largest market share due to:

  • Reduced immunogenicity

  • Advanced genetic engineering techniques

  • Use of phage/yeast display platforms

  • Transgenic mouse technologies

Humanized mAbs also account for significant revenue due to their extensive use in oncology and autoimmune disorders.

By Indication

  • Oncology (Largest Segment)

  • Inflammatory Diseases

  • Infectious Diseases

  • Autoimmune Diseases

  • Others

The dominance of oncology is attributed to rising cancer prevalence and expanding drug pipelines targeting multiple tumor types.

By End User

  • Research Institutes

  • Hospitals (Dominant Segment)

  • Others

Hospitals account for the largest share due to:

  • Increasing chronic disease hospitalizations

  • Advanced therapeutic infrastructure

  • Specialized oncology and autoimmune care units

  • Rising healthcare expenditure

Regional Analysis

North America – Market Leader

North America accounts for over 48% of the global market share due to:

  • Strong presence of major biopharma companies

  • High R&D investment

  • Frequent regulatory approvals

  • Advanced healthcare infrastructure

Increased funding for cancer research and biologics innovation continues to fuel demand.

Asia-Pacific – Fastest Growing Region

The Asia-Pacific region is projected to grow rapidly due to:

  • Expanding healthcare infrastructure

  • Rising government R&D initiatives

  • Increasing disease burden

  • Growing awareness of biologic therapies

Global manufacturers are expanding operations in emerging APAC markets.

BUYNOW:https://virtuemarketresearch.com/report/monoclonal-antibodies-market/enquire

Key Companies in the Monoclonal Antibodies Market

Major players include:

  • AbbVie Inc.

  • Bristol Myers Squibb

  • Amgen

  • F. Hoffmann-La Roche

  • Merck & Co., Inc.

  • Regeneron Pharmaceuticals

  • AstraZeneca

  • Johnson & Johnson

  • Eli Lilly and Company

  • Takeda Pharmaceutical Company Limited

  • GlaxoSmithKline plc

  • Novartis AG

Companies are adopting strategies such as:

  • Mergers & acquisitions

  • Strategic collaborations

  • Geographic expansion

  • Product portfolio diversification

CUSTOMISATION:https://virtuemarketresearch.com/report/monoclonal-antibodies-market/customization

Notable Market Developments

  • In January 2021, Eli Lilly and Company, Vir Biotechnology, and GlaxoSmithKline plc collaborated on COVID-19 antibody therapies.

  • In May 2021, Central Drugs Standard Control Organisation granted Emergency Use Authorization to Roche India.

  • Amgen partnered with Kyowa Kirin Co., Ltd. to develop KHK4083 for atopic dermatitis.

  • U.S. Food and Drug Administration granted Emergency Use Authorizations (EUA) for multiple COVID-19 monoclonal antibody therapies.

    Written by

    Virtue Market Research

    We are a strategic management firm helping companies to tackle most of their strategic issues and make informed decisions for their future growth. We offer syndicated reports and consulting services. Our reports are designed to provide insights on the constant flux in the global demand-supply gap of markets. We are a team with rich experience in management consulting ensuring high impact outputs for our clients. We maintain transparency with our clients and deal with 3D research policy i.e. Data Collection, Data Processing and Data Validation. Below are the key factors which are part of our research and its output: Information: Information that relates and makes sense to the clients products and markets Expertise: Expert guidance and inputs to provide authenticate and validated analysis Execution: Transparent and holistic methodology for execution backed by highly experienced expertise Machine Learning/Data Science/Python plays major role in our research process involving data collection/gathering, reaching out to targets for primaries, data analysis, visualization and others. Our focus is more on authenticate & validated data which enables us to provide impactful insights and analysis to our clients.

    More from Virtue Market Research

    Leave a Comment